Scarica l'app Stockscreener
9.23
2.99%
-0.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Precedente Chiudi:
$9.52
Aprire:
$9.59
Volume 24 ore:
978.17K
Relative Volume:
0.18
Capitalizzazione di mercato:
$2.01B
Reddito:
$51.95M
Utile/perdita netta:
$-265.94M
Rapporto P/E:
-6.4169
EPS:
-1.4384
Flusso di cassa netto:
$-216.89M
1 W Prestazione:
-0.91%
1M Prestazione:
+22.32%
6M Prestazione:
-19.90%
1 anno Prestazione:
+13.59%
Intervallo 1D:
$9.215
$9.75
Intervallo di 1 settimana:
$9.215
$9.955
Portata 52W:
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Nome
Ocular Therapeutix Inc
Settore
Industria
Telefono
781-357-4000
Indirizzo
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
9.23 | 2.07B | 51.95M | -265.94M | -216.89M | -1.4384 |
VRTX
Vertex Pharmaceuticals Inc
|
429.72 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
738.08 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
769.08 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.01 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.08 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-15 | Iniziato | Chardan Capital Markets | Buy |
| 2025-04-08 | Iniziato | William Blair | Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-11 | Iniziato | Needham | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-20 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-02-09 | Iniziato | BofA Securities | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-10 | Ripresa | Berenberg | Buy |
| 2021-08-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-11-13 | Reiterato | Raymond James | Strong Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-05-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Iniziato | Raymond James | Strong Buy |
| 2018-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-07-12 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-08-11 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
May 5 at 8 a.m. ET: Ocular Therapeutix to discuss Q1 results - Stock Titan
Ocular Therapeutix gains amid takeover speculation - MSN
OCUL stock surges overnight ahead of crucial wet AMD data readout, Sanofi takeover buzz builds - MSN
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data - Yahoo Finance
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences - The Manila Times
Ocular lines up May talks on AMD trial data and investor webcasts - Stock Titan
Ocular Therapeutix prices $475M stock offering - MSN
Avoiding Lag: Real-Time Signals in (OCUL) Movement - Stock Traders Daily
Ocular Therapeutix (OCUL) Is Up 8.2% After Positive Phase 3 AXPAXLI Data and FDA FeedbackWhat's Changed - Sahm
Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates - Sahm
Ocular Therapeutix (OCUL) Quarterly Preview | Q4 2025: Profit SurprisesRevenue Diversification - Xã Thanh Hà
OCUL (Ocular Therapeutix Inc.) reports narrower Q4 2025 loss than consensus estimates, driving a 10.84 percent one-day share rally.Social Investment Platform - Cổng thông tin điện tử tỉnh Tây Ninh
OCUL (Ocular Therapeutix Inc.) tops Q4 2025 EPS estimates, shares gain slightly even as quarterly revenue declines year over year.Earnings Quality - Cổng thông tin điện tử Tỉnh Sơn La
Ocular Therapeutix lines up senior leaders, retina experts for June 17 - Stock Titan
Ocular Therapeutix (OCUL) soars 10.4% ahead of business updates - MSN
Ocular Therapeutix releases additional phase 3 AXPAXLI data for wet AMD - Eyes On Eyecare
Ocular Therapeutix Reports Positive Trial Data for Macular Degeneration - HarianBasis.co
Ocular Therapeutix Data Strengthens AXPAXLI Durability Case And FDA Ambitions - Sahm
Ocular Therapeutix Hits Day High with Strong 10.84% Intraday Surge - Markets Mojo
Ocular Therapeutix Experiences Revision in Its Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
HC Wainwright lifts Ocular Therapeutix, Inc. (OCUL) price target following intravitreal implant FDA submission - MSN
Ocular Therapeutix (OCUL) Stock Short Interest Analysis (Underperforming) 2026-04-20Smart Money Flow - Xã Thanh Hà
Ocular Therapeutix (OCUL) Announces Additional Positive Data From the SOL-1 Phase 3 Superiority Trial of AXPAXLI - Insider Monkey
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix Stock Soars to Day High with 10.45% Surge - Markets Mojo
Ocular Therapeutix (NASDAQ:OCUL) Trading 10.2% HigherHere's What Happened - MarketBeat
Here is why Ocular Therapeutix (OCUL) is highly favored by hedge funds - MSN
Is It Time To Reconsider Ocular Therapeutix (OCUL) After Its Recent Share Price Swings? - Sahm
Discipline and Rules-Based Execution in OCUL Response - Stock Traders Daily
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study - Sahm
H.C. Wainwright reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
New Ocular SVP gets 300,000 stock options in inducement grant - Stock Titan
Aug EndMonth: Can Ocular Therapeutix Inc maintain its current growth rateWeekly Gains Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Large Ocular Therapeutix (OCUL) share gift to spouse disclosed - Stock Titan
William Blair reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
Ocular Therapeutix Inc Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD - marketscreener.com
Ocular Therapeutix presents additional wet AMD trial data By Investing.com - Investing.com Australia
William Blair Maintains Ocular Therapeutix(OCUL.US) With Buy Rating - Moomoo
OCUL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $21 - GuruFocus
What's Going On With Ocular Therapeutix Stock Monday?Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
HC Wainwright Reiterates "Buy" Rating for Ocular Therapeutix (NASDAQ:OCUL) - MarketBeat
Positive Week 52 Data Released for Ocular Therapeutix (OCUL) - GuruFocus
Is Ocular Therapeutix (OCUL) Quietly Recasting Its Retinal Strategy Around Axpaxli’s Phase 3 Design Choices? - Yahoo Finance
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD - The Manila Times
Ocular Therapeutix Presents New SOL-1 Data Reinforcing AXPAXLI's Efficacy and Durability in Wet AMD at VBS Meeting - Quiver Quantitative
Ocular Therapeutix presents additional wet AMD trial data - Investing.com
Ocular Therapeutix™ Announces Additional Positive Week 52 - GlobeNewswire
Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD - Bitget
Assessing Whether Ocular Therapeutix (OCUL) Looks Undervalued After Recent Mixed Share Price Performance - Yahoo Finance
Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ocular Therapeutix Inc Azioni (OCUL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kaiser Peter | Chief Development Officer |
Feb 23 '26 |
Sale |
8.28 |
2,810 |
23,267 |
269,108 |
| Heier Jeffrey S. | Chief Scientific Officer |
Feb 23 '26 |
Sale |
8.28 |
3,057 |
25,312 |
323,368 |
| Nayak Sanjay | Chief Strategy Officer |
Feb 23 '26 |
Sale |
8.28 |
1,759 |
14,565 |
330,653 |
| Waheed Nadia | Chief Medical Officer |
Feb 20 '26 |
Sale |
7.74 |
3,510 |
27,167 |
314,907 |
| LINDSTROM RICHARD L MD | Director |
Feb 20 '26 |
Buy |
7.66 |
60,229 |
461,354 |
246,933 |
0.45%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):